Thea Pharma Drug Patent Portfolio
Thea Pharma owns 4 orange book drugs protected by 10 US patents Given below is the list of Thea Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8637054 | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives | 08 Jul, 2031 | Active |
| US10864159 | Method and composition for treating ocular hypertension and glaucoma | 28 May, 2029 | Active |
| US9999593 | Method and composition for treating ocular hypertension and glaucoma | 28 May, 2029 | Active |
| US8759401 | Aqueous gel formulation and method for inducing topical anesthesia | 24 Jul, 2026 | Active |
| US6239113 | Topical treatment or prevention of ocular infections | 31 Mar, 2019 | Expired |
| US6569443 | Topical treatment or prevention of ocular infections | 31 Mar, 2019 | Expired |
| US7056893 | Topical treatment for prevention of ocular infections | 31 Mar, 2019 | Expired |
| US6861411 | Method of treating eye infections with azithromycin | 25 Nov, 2018 | Expired |
| US5886035 | Difluoroprostaglandin derivatives and their use | 18 Dec, 2017 | Expired |
| US6159458 | Sustained release ophthalmic compositions containing water soluble medicaments | 04 Nov, 2017 | Expired |
Latest Legal Activities on Thea Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Thea Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 May, 2024 | US10864159 |
|
Correspondence Address Change
Critical
| 23 Sep, 2022 | US8759401 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 23 Sep, 2022 | US8759401 |
|
Email Notification
Critical
| 09 Sep, 2022 | US8759401 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 09 Sep, 2022 | US8759401 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 17 Jan, 2022 | US8759401 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2022 | US8759401 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Dec, 2021 | US9999593 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 15 Dec, 2020 | US10864159 |
|
Recordation of Patent Grant Mailed
Critical
| 15 Dec, 2020 | US10864159 |
|
Email Notification
Critical
| 25 Nov, 2020 | US10864159 |
|
Issue Notification Mailed
Critical
| 24 Nov, 2020 | US10864159 |
| Dispatch to FDC | 12 Nov, 2020 | US10864159 |
|
Application Is Considered Ready for Issue
Critical
| 12 Nov, 2020 | US10864159 |
|
Issue Fee Payment Received
Critical
| 11 Nov, 2020 | US10864159 |
Thea Pharma's Drug Patent Litigations
Thea Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 12, 2017, against patent number US5886035. The petitioner Micro Labs Limited, challenged the validity of this patent, with Santen Pharmaceutical Co., Ltd. as the respondent. Click below to track the latest information on how companies are challenging Thea Pharma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5886035 | May, 2017 |
FWD Entered
(27 Nov, 2018)
| Santen Pharmaceutical Co., Ltd. | Micro Labs Limited |
Thea Pharma Drug Patents' Oppositions Filed in EPO
Thea Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 02, 2018, by Cooke, Richard. This opposition was filed on patent number EP14001862A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP20164602A | Oct, 2022 | Becker, Eberhard | Granted and Under Opposition |
| EP20164602A | Oct, 2022 | De Gregori, Antonella | Granted and Under Opposition |
| EP20164602A | Oct, 2022 | Cooke, Richard | Granted and Under Opposition |
| EP17000440A | Jan, 2021 | Cooke, Richard | Granted and Under Opposition |
| EP14001862A | Feb, 2018 | Cooke, Richard | Granted and Under Opposition |
Thea Pharma's Family Patents
Thea Pharma Drug List
Given below is the complete list of Thea Pharma's drugs and the patents protecting them.
1. Akten
Akten is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8759401 | Aqueous gel formulation and method for inducing topical anesthesia |
24 Jul, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Akten's drug page
2. Azasite
Azasite is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6239113 | Topical treatment or prevention of ocular infections |
31 Mar, 2019
(5 years ago)
| Expired |
| US6569443 | Topical treatment or prevention of ocular infections |
31 Mar, 2019
(5 years ago)
| Expired |
| US7056893 | Topical treatment for prevention of ocular infections |
31 Mar, 2019
(5 years ago)
| Expired |
| US6861411 | Method of treating eye infections with azithromycin |
25 Nov, 2018
(6 years ago)
| Expired |
| US6159458 | Sustained release ophthalmic compositions containing water soluble medicaments |
04 Nov, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Azasite's drug page
3. Iyuzeh
Iyuzeh is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8637054 | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives |
08 Jul, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Iyuzeh's drug page
4. Zioptan
Zioptan is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10864159 | Method and composition for treating ocular hypertension and glaucoma |
28 May, 2029
(4 years from now)
| Active |
| US9999593 | Method and composition for treating ocular hypertension and glaucoma |
28 May, 2029
(4 years from now)
| Active |
| US5886035 | Difluoroprostaglandin derivatives and their use |
18 Dec, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zioptan's drug page